Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)

INTRODUCTION: The The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhrenholt, Line, Schlemmer, Annette, Hauge, Ellen-Margrethe, Christensen, Robin, Dreyer, Lene, Suarez-Almazor, Maria E, Kristensen, Salome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624054/
https://www.ncbi.nlm.nih.gov/pubmed/31292181
http://dx.doi.org/10.1136/bmjopen-2018-028517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624054/
https://www.ncbi.nlm.nih.gov/pubmed/31292181
http://dx.doi.org/10.1136/bmjopen-2018-028517

Ejemplares similares